Stay updated on Nivolumab Combo Immuno-therapy Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo Immuno-therapy Clinical Trial page.

Latest updates to the Nivolumab Combo Immuno-therapy Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now shows Revision: v3.4.2, and the earlier funding lapse notice (Revision: v3.4.1) has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a general site notice about the lapse in government funding and NIH Clinical Center status, and updated the page revision to v3.4.1 while removing the previous v3.4.0 reference. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedThe study page now displays a glossary option and includes new metadata fields: Results First Posted, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and a new Revision: v3.4.0. The older items, including Results First Posted (Estimated), Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and the previous Revision: v3.3.4, have been removed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 on the page; this is a minor metadata change with no impact on study details or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page's Locations section was updated to add numerous locations across multiple countries and regions and to remove several existing locations, and a Revision: v3.3.3 tag was added.SummaryDifference2%

- Check78 days agoChange DetectedAdded 'Results Posted' with detailed safety and efficacy outcome measures, including definitions for dose-limiting toxicities and safety events. Timelines for assessments and links to the Study Protocol and Statistical Analysis Plan were also included.SummaryDifference3%

Stay in the know with updates to Nivolumab Combo Immuno-therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo Immuno-therapy Clinical Trial page.